Psoriasis: an opportunity to identify cardiovascular risk.
Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life. Recently, it has been demonstrated that not only do patients with psoriasis have an increased prevalence of cardiovascular risk factors, but an increased risk of myocardial infarction, and for those with severe disease, increased mortality. Dermatologists and other health professionals need to be cognizant of this association and ensure that cardiovascular risk factors are evaluated and treated appropriately in those patients with psoriasis. We review the association between psoriasis, atherosclerosis and inflammation, as well as some treatable cardiovascular risk factors that may prove beneficial in reducing a patient's cardiovascular risk.
Federman
D G
DG
Department of Medicine, VA Connecticut Health Care Center (11ACSL), 950 Campbell Ave., West Haven, CT 06516, USA. daniel.federman@va.gov
Shelling
M
M
Prodanovich
S
S
Gunderson
C G
CG
Kirsner
R S
RS
D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003925:Diabetic Angiopathies / Q000150:complications; D050171:Dyslipidemias / Q000150:complications; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D008297:Male; D009765:Obesity / Q000378:metabolism; D011565:Psoriasis / Q000150:complications* / Q000276:immunology; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000378:metabolism; D018417:Th1 Cells / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D007376:Interleukin-2; D042461:Vascular Endothelial Growth Factor A; D001241:Aspirin